US-China geopolitical tensions may extend to biotechnology as Chinese firms secure record $60B in cross-border deals in Q1 2026, dominating global biotech deal-making. US policymakers express concern over capital fueling China's industry growth.
China ranked third in a new global index measuring competitiveness in AI for biotechnology, healthcare and longevity, as the race to apply AI moves from chatbots and general-purpose models into regulated, data-heavy industries such as drug discovery, diagnostics and preventive medicine. The latest edition of the Global AI Competitiveness Index, released on Monday by Deep Knowledge Group, a consortium focused on deep-tech research, analytics and investment, ranked China behind only the US and UK...
The Cabinet of Ministers will also need to prepare proposals to expand the participation of biotechnology organizations in the implementation of the federal project "Professionalism"
